受賞歴・トピック
医学教育部フェロー（臨床腫瘍科）の山本一将先生が
第8回日本がんサポーティブケア学会学術集会（2023年6月22-24日・奈良）が主催する
一般演題の優秀演題賞に選ばれました。
演題名：タキサン系抗がん剤による爪障害に関するアンケート調査
アンケートにご協力いただきました皆様、誠にありがとうございました。
医学教育部フェロー（臨床腫瘍科）の奥村浩基先生が、
今年5月に臨床実習(クリニカルクラークシップ)に来られた東京大学医学部6年 呉 千恵さんと一緒に執筆した
NEJM誌「Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma」に対する
Letter「Consideration of liver toxicity is necessary applying the triplet regimen」が掲載されました！
著書
がん治療薬まるわかりBOOK 第2版
三浦裕司ほか
照林社 2022年3月16日刊
高齢者機能評価とレジメンでわかるがん薬物療法
三浦裕司、渡辺祥伍ほか
中外医学社 2022年9月30日刊
薬語図鑑：基礎薬学用語を現場で使える知識に訳してみました
三浦裕司、竹村弘司ほか
南山堂 2023年3月31日刊
あらゆる症例に対応できる！消化器がん薬物療法第3版
三浦裕司、陶山浩一ほか
羊土社 2023年3月15日刊
図解でスッキリ!抗がん薬の薬理作用
三浦裕司ほか
南江堂 2023年7月20日刊
泌尿器科・病理・放射線科腎盂・尿管・膀胱癌取扱い規約
三浦裕司ほか
医学図書出版 2021年8月10日刊
がん免疫療法ガイドライン 第3版
三浦裕司ほか
金原出版株式会社 2023年3月20日刊
がん薬物療法時の腎障害診療ガイドライン2022
陶山浩一ほか
ライフサイエンス出版 2022年11月1日刊
茎癌診療ガイドライン (2021年版)
三浦裕司ほか
医学図書出版 2021年7月28日刊
論文
2020年
2) Kizawa R, Hara T, Miura Y： Letter by Kizawa et al Regarding Article, "Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study" Circulation. 2020 Sep 15;142(11):e154-e155.
3) Aoyama Y, Kondoh C, Anno M, Takahashi T, Yoshino K, Kizawa R, Ozaki Y, Tanabe Y, Miura Y, Takano T: Malignant Spinal Cord Compression. Gan To Kagaku Ryoho. 2020 Jun;47(6):875-880
4) Miura Y, Ando M, Yamazaki K, Hironaka S, Boku N, Muro K, Hyodo I: Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2). Support Care Cancer. 2020 Nov 16. doi: 10.1007/s00520-020-05891-2. Online ahead of print.
5) Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coşkun HS, Gracian AC, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, and Bang YJ: Phase 3 trial of avelumab maintenance following first-line induction chemotherapy vs continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100. J Clin Oncol. Published online on November 16, 2020.
6) Naito Y, Aburatani H, Miura Y, Yoshino T, Tsuchihara K: et al. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol. 2020 Nov 29. doi: 10.1007/s10147-020-01831-6. Online ahead of print.
7) Nasu I, Shimano R, Kawazoe H, Nakamura T, Miura Y, Takano T, and Hayashi M: Patient-related risk factors for nausea and vomiting with standard antiemetics in patients with cancer receiving carboplatin: A retrospective study. Clin Ther 42:1975-1982, 2020.
8) Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, and Brufsky A: Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol 38:3138-3149, 2020.
9) Tsuda M, Ishiguro H, Toriguchi N, Masuda N, Bando H, Ohgami M, Homma M, Morita S, Yamamoto N, Kuroi K, Yanagita Y, Takano T, Shimizu S, and Toi M: Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. Cancer Med 9:9246–9255, 2020.
10) Ogasawara N, Saitoh S, Suzuki F, Kinowaki K, Masuda J Denpou H, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miura Y, Takano T, and Kumada H: Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography. Clin J Gastroenterol 13:1225–1232, 2020.
11) Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, and Ohno S: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials 21:391,2020.
12) Matsumoto K, Takahashi M, Sato K, Osaki A, Takano T, Naito Y, Matsuura K, Aogi K, Fujiwara K, Tamura K, Baba M, Tokunaga S, Hirano G, Imoto S, Miyazaki C, Yanagihara K, Imamura CK, Chiba Y, and Saeki T: A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. Cancer Med 9:3319-3327,2020.
13) Matsuoka YJ, Okubo R, Shimizu Y, Tsuji K, Narisawa T, Sasaki J, Sasai H, Akashi-Tanaka S, Hamaguchi T, Iwasa T, Iwata S, Kato T, Kurotani K, Maruyama D, Mori A, Ogawa A, Sakurai N, Shimazu T, Shimizu C, Tabuchi T, Takahashi M, Takano T, Tatematsu N, Uchitomi Y, Watanabe C, and Fukui T: Developing the structure of Japan's cancer survivorship guidelines using an expert panel and modified Delphi method. J Cancer Surviv 14:273–283,2020.
14) Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, Yasuno S, Morita S, Ohno S, and Toi M: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients: extended follow‑up of JBCRG‑cohort study 01. Breast Cancer 27:631–641,2020.
15) Tsuda H, Tsugawa K, Akiyama F, Horii R, Kurosumi M, Moriya T, Takano T, Takei H, Nakayama T, Miyagi Y, Yamauchi C, Yamashita T, Aogi K, Mukai H, Sugie T, Iwata H, and Masuda S: Histological classifcation of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition). Breast Cancer 27:309-321,2020.
16) Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, and Toyama T: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer 27:322-331,2020.
17) Takano T: The era of meta-analyses-based recommendations: How were the Japanese Breast Cancer Society Clinical Practice Guidelines for Systemic Treatment of Breast Cancer established? Breast Cancer 27:332-333,2020.
18) Miyashita M, Hattori M, Takano T, Toyama T, and Iwata H: Risks and benefts of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer 27:347-354,2020.
19) Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, and Ohno S: Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. Breast Cancer 27:389–398,2020.
20) Tanabe Y, Shiraishi S, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y, and Shimizu C: Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. BMC Cancer 20:325,2020.
21) Noda-Narita S, Shimomura A, Tanabe Y, Kawauchi J, Matsuzaki J, Takizawa S, Aoki Y, Shimizu C, Tamura K, Ochiya T：Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs. BMJ Support Palliat Care. 2020Jan14:bmjspcare-2019-001900.doi:10.1136/bmjspcare-2019-001900.Online ahead of print.
22) Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, and Toi M: A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Res Treat 180:715–724, 2020.
23) Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, and Tanigawara Y: CYP2D6 genotype–guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer (TARGET-1): a randomized, open-label, phase II study. J Clin Oncol 38:558-566, 2020.
24) Ueno T, Masuda N, Sato n, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, and Toi M: Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Jpn J Clin Oncol 50:3–11,2020.
25) Ogasawara N, Saitoh S, Suzuki F, Kinowaki K, Masuda J, Denpou H, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miura Y, Takano T, Kumada H: Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography. Clin J Gastroenterol. 2020 Dec;13(6):1225-1232.
26) Mitani S, Kadowaki S, Komori A, Kondoh C, Oze I, Kato K, Masuishi T, Honda K, Narita Y, Taniguchi H, Ando M, Tanaka T, Tajika M and Muro K: A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies. Adv Ther 37:2853–2864,2020.
27) Tomita Y, Tatsugami K, Nakaigawa N, Osawa T, Oya M, Kanayama H, Kondoh C, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Tanaka S, Kimura A and Tamada S: Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients. Int J Urol 27:952-959,2020.
28) Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y,Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K: Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. JAMA Oncol 6:1-9,2020.
29) Yamanaka T, Tatsushima K, Kondoh C, Takemura K, Masuda J, Ozaki Y, Tanabe Y, Miura Y, Takano T: Hypopituitarism. Gan To Kagaku Ryoho. 47:885-890, 2020.
30) Aoyama Y, Kondoh C, Anno M, Takahashi T, Yoshino K, Kizawa R, Ozaki Y, Tanabe Y, Miura Y, Takano T: Malignant Spinal Cord Compression. Gan To Kagaku Ryoho. 47:875-880,2020.
31) Takemura K, Nakayama S, Murashima N : A case report of porto-mesenteric vein thrombosis after laparoscopic sleeve gastrectomy, successfully treated with danaparoid sodium and antithrombin III, followed by rivaroxaban maintenance therapy. Portal Hypertension 2020;26: 159-163.
2019年
2) Akamatsu H, Harada H, Tokunaga S, Yoshimura N, Ikeda H, Oizumi S, Sugimoto N, Takano T, Murakami H, Nishimura Y, Yamamoto N, Nakagawa K: A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III Non-Small Cell Lung Cancer harboring EGFR mutations (WJOG6911L). Clinical Lung Cancer 20:e25-e27, 2019.
3) Yokoe T, Hayashida T, Nagayama A, Seki T, Takahashi M, Takano T, Abe T, Kitagawa Y: Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. The Oncologist 24:e347-e357, 2019.
4) Miura Y, Imamura CK, Uchino K, Kishida K, Matsubara N, Shinojima T, Kondo K, Hongo F, Yoshimura K, Tanigawara Y, Takano T. Individualized dosing of axitinib based on the first-dose AUC in patients with metastatic renal cell carcinoma. Clin Genitourinary Cancer. 2019;17(1):e1-e11
5) Miura Y, Horie S. The role of hormone therapy and chemotherapy in oligometastic prostate cancer. ESMO Open 2019;4:e000471
6) Jiao S, Subudhi S, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell 179:1177-1190.e13, 2019
7) Ozaki Y, Masuda J, Takano T. Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. N Engl J Med. 2019 Jun 13;380(24):2382.
8) Takahashi M, Ozaki Y, Kizawa R, Masuda J, Sakamaki K, Kinowaki K, Umezu T, Kondoh C, Tanabe Y, Tamura N, Miura Y, Shigekawa T, Kawabata H, Baba N, Iguchi H, Takano T. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer. 2019 Oct 22;19(1):980.
9) Miura S, Naito T, Mitsunaga S, Omae K, Mori K, Inano T, Yamaguchi T, Tatematsu N, Okayama T, Morikawa A, Mouri T, Tanaka H, Kimura M, Imai H, Mizukami T, Imoto A, Kondoh C, Shiotsu S, Okuyama H, Ueno M, Takahashi T, Tsuji T, Aragane H, Inui A, Higashiguchi T, Takayama K: A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. BMC Cancer. 19:528, 2019.
2018年
2) Masuda N, Toi M, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y, Kasai H, Morita S, Sakurai T, Ohno S. Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial. Breast Cancer 25:407-415, 2018
3) Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study. Current Medical Research and Opinion 34, 49–54, 2018
4) Miura, Y, Sukawa Y, Hironaka S, Mori M, Nishikawa Kazuhiro, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa Kazuo, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric Cancer 21, 84–95, 2018
5) Ozaki Y, Tanabe Y, Tamura N, Ogura T, Kondoh C, Miura Y, Yoshimura K, Kawabata H, Takano T. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study. Breast Cancer 25:343-349, 2018
6) Powles T, Durán I, van der Heijden M.S, Loriot Y, Vogelzang N.J, De Giorgi U, Oudard S, Retz M.M, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel E.E, Banchereau R, Hegde P.S, Mariathasan S, Cui N, Shen X, Derleth C.L, Green M.C, Ravaud A. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391:748-757, 2018
7) Motoshima T, Miura Y, Wakigami N, Kusada N, Takano T, Inoshita N, Okaneya T, Sugiyama Y, Kamba T, Takeya M, Komohara Y. Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma. Medical Molecular Morphology. 51:57-63, 2018
8) Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, Danaee H, Asato T, Kalebic T, Wang H, and Doi T. TAK-264 (MLN0264) in previously treated Asian patients with advanced gastrointestinal carcinoma expressing guanylyl cyclase C: results from an open-label, non-randomized phase 1 study. Cancer Res Treat 50: 398-404, 2018
9) Oka S, Inoshita N, Miura Y, Oki R, Miyama Y, Nagamoto S, Ogawa K, Sakaguchi K, Kondoh C, Kurosawa K, Urakami S, Takano T, Okaneya T. Prognostic value of BAP1 expression in clear cell renal cell carcinoma with inferior vena cava tumor thrombosis. Urol Oncol. May 28, 2018 Epub ahead, doi: 10:1016/j.urolonc.2018.04.015
10) Funakoshi T, Horimatsu T, Nakamura M, Shiroshita K, Suyama K, Mukoyama M, Mizukami T, Sakurada T, Baba E, Tsuruya K, Nozaki A, Yahata K, Ozaki Y, Ubara Y, Yasui H, Yoshimoto A, Fukuma S, Kondo N, Matsubara T, Matsubara K, Fukuhara S, Yanagita M, Muto M. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. ESMO Open. 2018 Feb 23;3(2).
11) Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T: A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. The Breast 40:67-75, 2018
12) Yokoe T, Hayashida T, Nagayama A, Seki T, Takahashi M, Takano T, Abe T, Kitagawa Y: Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. The Oncologist 2018 (in press)
13) Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, and Toi M: Survival outcomes of retreatment with trastuzumab and cytotoxic chemotherapy for HER2-positive recurrent patients with breast cancer who had been treated with neo/adjuvant trastuzumab plus multidrug chemotherapy: a Japanese multicenter observational study. Breast Cancer (Auckl), published online on July 5, 2018
14) Akamatsu H, Harada H, Tokunaga S, Yoshimura N, Ikeda H, Oizumi S, Sugimoto N, Takano T, Murakami H, Nishimura Y, Yamamoto N, Nakagawa K: A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III Non-Small Cell Lung Cancer harboring EGFR mutations (WJOG6911L). Clinical Lung Cancer 2018 (in press)
15) Kuwayama T, Nakamura S, Hayashi N, Takano T, Tsugawa K, Sato T, Kitani A, Okuyama H, and Yamauchi H: Randomized multicenter phase II trial of neoadjuvant therapy comparing weekly nab-paclitaxel followed by FEC with docetaxel followed by FEC in HER2- early-stage breast cancer. Clin Breast Cancer. published online on Jun 27, 2018
16) Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, and Ohno S: A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. Jpn J Clin Oncol 48:855–859, 2018
17) Sasaki T, Kato Y, Sato A, Usui N, Baba E, Takano T, Susumu N, Ohnishi K, Nishimoto H, Kiura K: A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors. J Pharm Health Care Sci 4:2, 2018
18) Miura Y, Imamura CK, Uchino K, Kishida K, Matsubara N, Shinojima T, Kondo K, Hongo F, Yoshimura K, Tanigawara Y, Takano T. Individualized dosing of axitinib based on the first-dose AUC in patients with metastatic renal cell carcinoma. Clin Genitourinary Cancer. Nov 2018 in press.
19) Kondoh C, Miura Y, Yamanaka T. Sunitinib alone or after nephrectomy in renal cancer. N Engl J Med.379:1877-8.
20) C Kondoh, S Kadowaki, A Komori, Y Narita, H Taniguchi, T Ura, M Ando, K Muro. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5‑fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan. Gastric Cancer 21 (6), 1050-1057, 2018.
2017年
2) Tomizawa K, Miura Y, Fukui Y, Hanaoka Y, Toda S, Moriyama J, Inoshita N, Ozaki Y, Takano T, Matoba S, and Kuroyanagi H. Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab. Int J Surg Case Rep 31:128-131, 2017
3) Watanabe J, Ito Y, Saeki T, Masuda N, Takano T, Takao S, Nakagami K, Tsugawa K, Nakagawa S, Kanatani K, and Nakayama T. Safety evaluation of trastuzumab emtansine in Japanese patients with HER2-positive advanced breast cancer. In vivo 31:493-500, 2017
4) Miura Y, Inoshita N, Ikeda M, Oki R, Ozaki Y, Tanabe Y, Kuosawa K, Urakami S, Kono T, Okaneya T, and Takano T. Loss of BAP1 protein expression in metastatic sites of the first recurrence to predict prognosis in patients with clear cell renal cell carcinoma. Urologic Oncology 35:386–391, 2017
5) Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y. Paclitaxel‑induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol 79:1179–1186, 2017
6) Koganemaru S, Inoshita N, Miura Y, Miyama Y, Fukui Y, Ozaki Y, Tomizawa K, Hanaoka Y, Toda S, Suyama K, Tanabe Y, Moriyama J, Fujii T, Matoba S, Kuroyanagi H, Takano T. Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. Cancer Science 108:853-858, 2017
7) Ozaki Y, Shindoh J, Miura Y, Nakajima H, Oki R, Uchiyama M, Masuda J, Kinowaki K, Kondoh C, Tanabe Y, Tanaka T, Haruta S, Ueno M, Kitano S, Fujii T, Udagawa H, Takano T. Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: A case report. BMC Cancer 17:778, 2017
8) Ishizuka N, Takano T, Miura Y, Suyama K, Shimomura A, and Matsushima E. Psychological distress and Resilience among partners of cancer patients receiving outpatient chemotherapy. International Journal of Clinical Medicine, 8:481-495, 2017
9) Tomizawa K, Miura Y, Fukui Y, Hanaoka Y, Toda S, Moriyama J, Inoshita N, Ozaki Y, Takano T, Matoba S, Kuroyanagi H. Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab: A case report. Int J Surg Case Rep 2017;31:128-31
10) Suyama K, Miura Y, Takano T, Iwase H. Chemotherapy for Patients with Renal Dysfunction. J Clin Exp Oncol 2017;6:1
11) Miura Y, Inoshita N, Ikeda M, Miyama Y, Oki R, Oka S, Kondoh C, Ozaki Y, Tanabe Y, Kurosawa K, Urakami S, Kohno T, Okaneya T, Takano T. Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma. Urol Oncol. 2017;35:386-91.
2016年
1) Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Science 107:1843-1850, 2016
2) Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, and Ohashi Y. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 17:90-98, 2016
2015年
*Kitasato University, Kanagawa, Japan
2) Ozaki Y, Miura Y, Koganemaru S, Suyama K, Inoshita N, Fujii T, Hashimoto M, Tamura T, Takeuchi K, Takano T. Ewing sarcoma of the liver with multilocular cystic mass formation: a case report. BMC Cancer 15:16, 2015
3) Body JJ*, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, and Kostenuik PJ. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 51:1812–1821, 2015
*CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
4) Yamashiro H*, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, and Toi M. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. Int J Clin Oncol 20:709-22, 2015
*Department of Breast Surgery, Tenri Hospital, Nara, Japan
5) Ryu MH*, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, Song EK, Cho SH, Kang WK, Yang SH, Zang DY, Shin DB, Park SR, Shinozaki K, Takano T, Kang YK. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol 26:2097-2101, 2015
*Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2014年
*Hyogo Cancer Center
2) Soma S*, Tsuta K, Takano T, Hatanaka Y, Yoshida A, Suzuki K, Asamura H, and Tsuda H. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma. Pathol Res Pract 210:155-160, 2014
*National Cancer Center Hospital
3) Tomizawa K, Suyama K, Matoba S, Hanaoka Y, Toda S, Moriyama J, Shimomura A, Miura Y, Kumada H, Kuroyanagi H, Takano T. The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection. Med Oncol 31:212, 2014.
4) Masuda N*, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S and Toi M. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer Cancer Chemother Pharmacol 74:229-38, 2014
*Osaka National Hospital
5) Miura Y, Imamura CK, Fukunaga K, Katsuyama Y, Suyama K, Okaneya T, Mushiroda T, Ando Y, Takano T, and Tanigawara Y. Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype. BMC Cancer 14:964, 2014
6) Ozaki Y, Miura Y, and Takano T. Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med 371:2233-2234, 2014
2013年
2) Miura Y, Theriault RL, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H, and Takano T. The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. J Cancer 4:519-523, 2013
3) Miura Y, Suyama K, Shimomura A, Miyakawa J, Kobayashi H, Uki A, Okaneya T, and Takano T. Radiation-induced esophagitis exacerbated by everolimus. Case Rep Oncol 6:320-324, 2013
4) Shitara K*, Yuki S, Yamazaki K, Naito Y, Fukushima H, Komatsu Y, Yasui H, Takano T, and Muro K. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. J Cancer Res Clin Oncol. 139:595-603, 2013
*National Cancer Center Hospital East
5) Suyama K, Ikeda M, Suzuki E, Kojima M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Okusaka T, Furuse J. Early relapse of unresectable gallbladder cancer after discontinuation of gemcitabine monotherapy administered for 5 years in a patient who had complete response to the treatment. Case Rep Oncol. 2013 Oct 24;6(3):531-7
6) Sagara Y*, Sato K, Fukuma E, Higaki K, Mizutani M, Osaki A, Takano T, Tokuda Y, Ohno S, Masuda N, Suzuki M, and Saeki T. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer. Jpn J Clin Oncol 43:865–873, 2013
*Department of Breast Oncology, Sagara Hospital
2012年
2) Akiyama S, Suyama K, and Takano T. Colorectal-Cancer ScreeningN Engl J Med366:2129-2131, 2012
3) Kaji D, Miura Y, and Takano T. Adjuvant trastuzumab in HER2-positive breast cancerN Engl J Med366:663-666, 2012
201年
2) Koichi Suyama, Yoichi Naito, Kiyotaka Yoh, et al. "Development of Cushing’s Syndrome During Effective Chemotherapy for Small Cell Lung Cancer"Internal Medicine50: 335-338, 2011
3) Tsubokura M, Miura Y, Itokawa T, Murata K, Takei N, Higaki T, Murashige N, Kami M, Komatsu T. Fatal Dysrhythmia Following Initiation of Lansoprazole During a Long-Term Course of Voriconazole.J Clin Pharmacol.2011 Oct;51(10):1488-90.
4) Toshimi Takano. Investigator-driven clinical trials including translational research in Japan: West Japan Oncology Group (WJOG). Ann Oncol 22 (Suppl 9):ix22, 2011
5) Suyama K, Yoshino T, Bando H, et al. Difference in overall survival in colorectal cancer patients with the KRAS pG13D and other KRAS mutations after the failure of 5-fluorouracil, oxaliplatin, and irinotecan. Ann Oncol 22 (Suppl 9):ix26, 2011
6) Hanaoka M, Takano T, and Kawabata H. Exemestane for breast-cancer prevention N Engl J Med 365:1056-1058, 2011
7) Shigeta K, Naito Y, and Takano T. Early prostate cancer — treat or watch? N Engl J Med 365:568-569, 2011
2010年
2) Naito Y, Mukai H, Nagai S. Elderly breast cancer therapy: a Japanese experience. Jpn J Clin Oncol 2010 Aug;40(8):717-21
3) Naito Y, Goto K, Nagai K, et al. Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer. Chest 2010 Dec;138(6):1411-7
4) Naito Y, Miura Y, Takano T. Neoadjuvant chemotherapy or primary surgery in advanced ovarian cancer. N Engl J Med 2010 Dec 9;363(24):2371
5) Shigeta K, Miura Y, Naito Y, Takano T. Cabazitaxel for castration-resistant prostate cancer. Lancet 2011 Jan 8;377(9760):121
6) Tsubokura M, Miura Y, Itokawa T, et al. Fatal Dysrhythmia Following Initiation of Lansoprazole During a Long-Term Course of Voriconazole. J Clin Pharmacol 2010 Nov 23. [Epub ahead of print]
7) Tsubokura M, Miura Y, Itokawa T, et al. Failure of liver function tests in predicting drug clearance of chemotherapeutic agents in a patient who had recovered from hepatic congestion. Br J Clin Pharmacol 2010 Aug;70(2):277-9
学会発表
2020年
2) Moehler M, Dvorkin M, Özgüroğlu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coşkun HS, Gracian AC, Takano T, Wong R, Safran H, Vaccaro GM, Boku N, Conti I, Hong J, Xiong H, Taieb J, and Bang YJ: Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line chemotherapy vs continuation of chemotherapy for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC). American Society of Clinical Oncology Gastrointestinal (ASCO GI 2020) J Clin Oncol. 2020;38(suppl 4): Abstract 278. 2020.1.23-25.
3) Hara H, Takeno A, Yasui H, Imamura H, Akamatsu H, Fujitani K, Nakane M, Kondoh C, Yukisawa S, Nasu J, Miyata Y, Makiyama A, Ishida H, Yoshida N, Matsumura E, Ishigami M, Sugihara M, Ochiai A: Doi T. DS-Screen: Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer population. American Society of Clinical Oncology, Gastrointestinal Cancers Symposium 2020. Poster session #431. 2020.1-23-25.
4) Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Kondoh C, Segawa Y, Takahashi S, Yasuo I, Kidera Y, Fukuoka K, Nakamura Y, Chiba Y, Nishio K, Nakagawa K, and Hayashi H: NivoCUP: An open label phase 2 study on the efficacy of Nivolumab in cancer of unknown primary (CUP). Americal Society of Clinical Oncology, Virtual Scientific Program 2020. Clinical Science Symposium, Developmental Therapeutics – immunotherapy.#106. 2020.5.25.
5) Kurozumi S, Yokoe T, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Shimokawa M, and Takano T: Real-world analysis of the treatment beyond trastuzumab-emtansine for HER2-positive metastatic breast cancer: A multi-central cohort study (WJOG12519B). ASCO2020. 2020.5.29-6.2.
6) 大野真司、岩谷胤生、北野敦子、桜井なおみ、田辺裕子、 山内智香子、五十嵐中、久芳さやか、原文堅、佐伯澄人：2019年度 班研究課題 日本における乳癌治療による経済的負担への意識に関する研究 第3回日本腫瘍循環器学会学術集会 ｼﾝﾎﾟｼﾞｳﾑ３「腫瘍循環器を専門にして発展させるために」田辺裕子 S3-2 腫瘍循環器における腫瘍内科としての役割 ～女性医師の立場から～．第28回日本乳癌学会 班研究報告，2020.9.12.
7) Kizawa R, Ozaki Y, Tanabe Y, Miura Y, Takano T and Iguchi H：悪性腫瘍骨転移症例に対する免疫ﾁｪｯｸﾎﾟｲﾝﾄ阻害薬とﾃﾞﾉｽﾏﾌﾞ併用療法の効果に関する後方視的研究．第69回共済医学会，横浜，2020.9.30.
8) 三浦裕司：尿路上皮がんの臨床試験の結果から見えてきた、がん免疫療法の特性とﾊﾞｲｵﾏｰｶｰ〜化学療法との併用についての考察〜．ｽﾎﾟﾝｻｰﾄﾞｾﾐﾅｰ2，SS2-2第24回日本がん免疫学会，2020.10.8．
9) Ozaki Y, Mukohara T, Tsurutani J, Takahashi M, Matsumoto K, Futamura M, Masuda N, Kitano S, Yoshimura K, Minami H, Takano T: A multicenter Phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial. SABCS-1, The 28th Annual Meeting of the Japan Breast Cancer Society, Oct 9-31,2020.
10) Tsurutani J, Ohtani S, Takano T, Modi S, Cameron D, Lee C, Wang Y, Saxena K, Saito K, Nishijima S, Iwata H: A phase 3 trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs chemotherapy of investigator's choice in HER2-low metastatic breast cancer. P-24-18, The 28th Annual Meeting of the Japan Breast Cancer Society, Oct 9-31,2020.
11) 小林蓉子、田村宜子、栗川美智子、田中希世、木脇圭一、高野利実、中澤英樹、三浦大周、門脇正美、川端英孝：浸潤性小葉癌の術前画像診断と臨床病理学的特徴の検討 Imaging and clinicopathological characteristic of invasive lobular carcinoma. P-11-127 第28回日本乳癌学会学術総会，2020.10.9-31.
12) 川口駿、栗川美智子、田中希世、小林蓉子、佐藤順一朗、尾崎由紀範、木脇圭一、田辺裕子、田村宜子、門脇正美、三浦大周、中澤英樹、藤森賢、高野利実、藤井丈士、川端英孝：乳癌の内胸ﾘﾝﾊﾟ節転移に対する外科的切除について～単施設ｹｰｽｼﾘｰｽﾞ Surgical resection of internal mammary nodes involved in breast cancer: A single center case study. P-12-138 第28回日本乳癌学会学術総会，2020.10.9-31.
13) 久野真弘、栗川美智子、田中希世、小林蓉子、佐藤順一郎、尾崎由紀範、木脇圭一、田辺裕子、田村宜子、門脇正美、三浦大周、中澤英樹、高野利実、藤井丈士、川端英孝：ﾎﾙﾓﾝ受容体陽性HER2受容体陰性乳がんに対するOncotype DxとClinical Riskによる分類 施設内検討 Clinical Utility of Oncotype Dx & Clinical Risk for Guiding Treatment in HR(+)HER2(-) Breast Cancer.P-22-270第28回日本乳癌学会学術総会，2020.10.9-31.
14) Yasojima H, Takano T, Masuda N, Hattori M, Tsugawa K, Inoue K, Matsumoto K, Ohtani S, Ishikawa T, Yamamoto K, Nohata N, Karantza V, Cortes J, Iwata H: Pembrolizumab + Chemotherapy vs Chemotherapy in Metastatic TNBC: KEYNOTE-355 Japanese Subgroup Data. OR-08-2, The 28th Annual Meeting of the Japan Breast Cancer Society, Oct 14, 2020.
15) 西村明子、横江隆道、黒住献、能澤一樹、尾崎由記範、前田哲代、矢崎秀、大西舞、藤本章博、中山紗由香、坪口裕子、酒井瞳、緒方美里、寺田満雄、尾上琢磨、伊坂泰嗣、萩尾加奈子、下村昭彦、下川元継、高野利実：転移性HER2陽性乳癌に対するT-DM1後の治療の臨床効果に関する多施設共同ｺﾎｰﾄ研究(WJOG12519B) Real-world study of treatments after T-DM1 for HER2-positive metastatic breast cancer (WJOG12519B). OR-07-2, The 28th Annual Meeting of the Japan Breast Cancer Society, Oct 14,2020.
16) 大谷彰一郎、佐治重衡、長谷川善枝、藤澤知巳、柏葉匡寛、石田孝宣、山本豊、石川孝、永井成勲、芳林浩史、松本光史、相良安昭、北田正博、高野利実、髙田正泰、増田慎三、平成人、森田智視、大野真司、戸井雅和：進行乳癌に対するwPTX+BV導入療法後のﾎﾙﾓﾝ維持療法の有用性; JBCRG BOOSTER試験 A randomized P2 study evaluating efficacy of maintenance endocrine therapy following PTX+Bev in ABC. OR-06-2 第28回日本乳癌学会学術総会，2020.10.14.
17) 三浦裕司：高齢腎癌患者に対する全身薬物療法．ｼﾝﾎﾟｼﾞｳﾑ3，S3-1，第6回日本泌尿器腫瘍学会，2020.10.24.
18) Ozaki Y, Kitano S, Tsurutani J, Iwasa T, Takahashi M, Mukohara T, Mausuda N, Futamura M, Minami H, Matsumoto K, Kawabata H, Yamashita M, Yoshimura K, Takano T: Immunological analysis of the combination therapy of Nivolumab, Paclitaxel and Bevacizumab in patients with HER2-negative MBC in NEWBEAT trial (WJOG9917BTR).PS4-14. 2020.12.8-11.
19) Masuda J, Tsurutani J, Masuda N, Futamura M, Matsumoto K, Aogi K, Takahashi M, Iwata H, Iwasa T, Mukohara T, Yoshimura K, Ueno T, Takano T: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer: WJOG11418B NEWFLAME trial. SABCS2020.PS12-10. 2020.12.8-12.
20) 三浦裕司：陰茎癌に対する全身化学療法 UP TO DATE 10陰茎癌に対する診断と治療戦略．UD10-3．第108回日本泌尿器科学会，2020.12.24.
21) Miura Y: Proffered Paper Session on GU Cancer, Discussant. ESMO Asia Virtual Congress 2020
22) 近藤千紘、玉田聡、松原伸晃、水野隆一、木村剛、穴井智、冨田善彦、M Chen, RF. Perini、M Li、松田健司、田中義信、BI. Rini：転移性腎細胞がんの一次治療におけるﾍﾟﾑﾌﾞﾛﾘｽﾞﾏﾌﾞ＋ｱｷｼﾁﾆﾌﾞとｽﾆﾁﾆﾌﾞの比較検討：KEYNOTE-426試験 日本人集団の成績．癌治療学会優秀演題O36-5，2020.
23) Kondoh C, Bae MK, Tamada S, Matsubara N, Lee HJ, Mizuno R, Ani S, Kimura G, Tomita Y, Chang CH, JWC Chang, Lin J, Perini R, Molife LR, T Powles, B Rini, HJ Chung: Pembrolizumab Plus Axitinib vs Sunitinib in Metastatic Renal Cell Carcinoma. Outcomes of the KEYNOTE-426 Study in Patients From Eastern Asia. European Society of Medical Oncology Asia Virtual Congress 2020. Proffered paper session on Genitourinary tumours. 2000.
2019年
2) Ozaki Y, Takahashi M, Kizawa R, Masuda J, Kondoh C, Tanabe Y, Tamura N, Miura Y, Tamura N, Shigekawa T, Kawabata H, Baba N, Iguchi H, and Takano T: Atypical femoral fracture in breast cancer patients with bone metastasis receiving denosumab therapy: multi-center retrospective analysis. P349, 16th St. Gallen International Breast Cancer Conference 2019, Vienna, Austria, Mar 20-23, 2019
3) Matsumoto K, Futamura M, Miyaki T, Iwasa T, Imoto S, Doi M, Tokunaga S, Aogi K, Yoshimura K, and Takano T: A phase 2 study evaluating dose dense AC (ddAC) followed by dose dense paclitaxel (ddP) supported by 3.6mg peg-filgrastim (ddAC-ddP3.6) for patients (pts) with primary breast cancer (PBC) in Japan -WJOG9016B. 16th St. Gallen International Breast Cancer Conference 2019, Vienna, Austria, March 20-23, 2019
4) Iwata H, Yamashita T, Inoue K, Takahashi M, Masuda N, Yamauchi T, Yamamoto Y, Takano T, Niikura N, Nakayama T, Takashima N, Matsumoto K, Sagara Y, Fujii T, Hattori T, Sekiguchi R, and Wilke C: Alpelisib (ALP)+fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial. PS1-3, 2019 the Japanese Society of Medical Oncology Annual Meeting, July 18, 2019
5) Miura Y, Motoshima T, Inoshita N, Okaneya T, Takano T, and Komohara Y: Immune microenvironment in clear cell type renal cell carcinoma with loss of PBRM1 protein expression. MO1-9-2, 2019 the Japanese Society of Medical Oncology Annual Meeting, July 18, 2019
6) Ozaki Y, Matsumoto K, Nishimura M, Futamura M, Miyagi H,
Tsurutani J, Iwasa T, Imoto S, Doi M, Tokunaga S, Aogi K, Yoshimura K, Kitagawa K, Sagara Y, Baba M, Nagai N, and Takano T: A phase 2 study evaluating ddAC-ddPTX supported by peg-filgrastim for patients with primary breast cancer -WJOG9016B-. O1-8-5, 2019 the Japanese Society of Medical Oncology Annual Meeting, July 18, 2019
7) Yamanaka T, Kondoh C, Miura Y, Takahashi M, Masuda J, Ozaki Y, Tanabe Y, Yano A, Hagiwara K, Ogawa K, Nagamoto S, Sakaguchi K, Urakami S, Oakaneya T, and Takano T: Clinical course of hemodialysis patients with metastatic renal cell carcinoma: a single-center retrospective analysis. P1-109, 2019 the Japanese Society of Medical Oncology Annual Meeting, July 18, 2019
8) Takahashi M, Ozaki Y, Kizawa R, Masuda J, Sakamaki K, Kinowaki K, Umezu T, Kondoh C, Tanabe Y, Tamura N, Miura Y, Shigekawa T, Kawabata H, Baba N, Iguchi T, and Takano T: Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy. P1-236, 2019 the Japanese Society of Medical Oncology Annual Meeting, July 18, 2019
9) Shoji H, Kudo-Saito C, Takaishi H, Takahashi N, Denda T, Kawakami T, Yamaguchi K, Furuse J, Morikawa T, Takano T, Sawada R, Miyamoto T, Imazeki H, Aoki K, Muro K, and Boku N: A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR). MS1-4, 2019 the Japanese Society of Medical Oncology Annual Meeting, July 18, 2019
10) Ozaki Y, Miura Y, Yamanaka T, Takemura K, Kizawa R, Takahashi M, Masuda J, Kondoh C, Tanabe Y, and Takano T: Combined treatment with nivolumab plus denosumab for various cancers with bone metastasis: retrospective study. P2-201, 2019 the Japanese Society of Medical Oncology Annual Meeting, July 19, 2019
11) Kizawa R, Miura Y, Oda Y, Nagaoka Y, Masuda J, Ozaki Y, Kondoh C, Moriguchi S, Takahashi Y, Ogawa K, Tanabe Y, Taniguchi S, Okaneya T, Kishi A, Hayashi N, Kishi K, Takano T: Eosinophilia during treatment of immune checkpoint inhibitors predicts succeeding onset of immune-related adverse events. MO3-10-4, 2019 the Japanese Society of Medical Oncology Annual Meeting, July 20,2019.
12) Takano T: Systemic therapy for metastatic breast cancer EL25 2019 the Japanese Society of Medical Oncology Annual Meeting, July 18-20,2019.
13) Ozaki Y, Takahashi M, Kizawa R, Masuda J, Sakamaki K, Kinowaki K, Umezu T, Kondoh C, Tanabe Y, Tamura N, Miura Y, Shigekawa T, Kawabata H, Baba N, Iguchi H, and Takano T: Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. 第68回共済医学会，札幌，2019.10.23.
14) Miura Y: Systemic therapy for elderly patients with metastatic renal cell carcinoma. Ann Oncol 30 (vi48), suppl 6, 2019.
15) Miura Y, Motoshima T, Inoshita N, Okaneya T, Takano T, Komohara Y: Immune microenvironment in clear cell type renal cell carcinoma with loss of PBRM1 protein expression.Ann Oncol 30 (vi93), suppl 6, 2019.
16) Ozaki Y, Takahashi M, Kizawa R, Masuda J, Kondoh C, Tanabe Y, Miura Y, Tamura N, Shigekawa T, Kawabata H, Baba N, Iguchi H, Takano T: Atypical femoral fracture in breast cancer patients with bone metastasis receiving denosumab therapy: multi-center retrospective analysis. SGBCC 2019.
17) Ozaki Y, Masuda J, Kizawa R, Takahashi M, Kurikawa M, Tanaka K, Kobayashi Y, Kondoh C, Tamura N, Tanabe Y, Miura Y, Kawabata H, Takano T: Dose-dense doxorubicin and cyclophosphamide (ddAC) followed by taxane (T) for patients with early breast cancer in Japan: A retrospective study. PO038. GBCC 2019.
18) Ozaki Y, Miura Y, Yamanaka T, Takemura K, Kizawa R, Takahashi M, Masuda J, Kondoh C, Tanabe Y, Takano T: Combined treatment of patients with bone metastases from various cancers with nivolumab plus denosumab: a retrospective study. ASCO2019.
19) Ozaki Y, Takano T: A multicenter Phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial. 日本乳癌学会関東地方会，2019.12.7.
20) Ozaki Y, Mukohara T, Tsurutani J, Takahashi M, Matsumoto K, Futamura M, Masuda N, Kitano S, Yoshimura K, Minami H, Takano T: A multicenter Phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial. SABCS2019. PD1-03.
21) Masuda J, Tsurutani J, Masuda N, Futamura M, Matsumoto K, Aogi K, Takahashi M, Iwata H, Iwasa T, Mukohara T, Yoshimura K, Ueno T, Takano T: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial) SABCS2019.
22) Kondoh C, Ichinari Y, Morita H, Suyama H, Yoshii Y, Ezura M, Fujisawa Y, Iihara H, Kariya M, Matsumoto N, Nakashima S, Osato Y, Terasaki F, Yamagami M, Futamura M, Saji S, NT Ueno: Expectations and challenges for TeamOncology workshops. Japanese Society of Medical Oncology Congress. P1-254,2019.
23) Kondoh C: Discussion -Malignant Ureteral Obstruction-. Japanese Society of Medical Oncology Congress, Presidential Session 2, PS2-4,2019.
24) Kizawa R, Miura Y, Oda Y, Nagaoka Y, Masuda J, Ozaki Y, Kondoh C, Moriguchi S, Takahashi Y, Ogawa K, Tanabe-Hashimoto Y, Taniguchi S, Okaneya T, Kishi A, Hayashi N, Takaya H, Takano T: Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs). European Society of Medical Oncology Congress. # 2350, 2019.
25) 高野利実：一般病院の腫瘍内科医からみた在宅療養 ｼﾝﾎﾟｼﾞｳﾑ4「緩和ｹｱにおける地域連携～患者の希望を効果的につなぐ～」．第24回日本緩和医療学会学術大会，2019.6.21.
26) 高野利実：臨床試験とｶﾞｲﾄﾞﾗｲﾝ Patient Advocate Program．第17回日本臨床腫瘍学会学術集会 JSMO2019@Kyoto，2019.7.19.
27) 高野利実：ｲｰﾋﾟｰｴｽ乳がんの薬物療法 症例を通して学ぶｻﾎﾟｰﾃｨﾌﾞｹｱ「乳がん」．第4回日本がんｻﾎﾟｰﾃｨﾌﾞｹｱ学会学術集会，青森，2019.9.6.
28) 山中太郎、冨田大輔、宇留賀公紀、諸川納早、森口修平、高橋由以、小川和雄、村瀬亨子、花田豪郎、宮本篤、岸一馬、高谷久史：「横紋筋融解症と急性腎不全で発症したﾚﾌﾟﾄｽﾋﾟﾗ症の1例」．第68回日本感染症学会東日本地方会・第66回日本化学療法学会東日本支部 合同学会 演題番号 109，2019.10.17.
29) 高野利実：乳癌とｱﾃｿﾞﾘｽﾞﾏﾌﾞ ～乳癌にもICIの時代が到来～ ｲﾌﾞﾆﾝｸﾞｾﾐﾅｰ．第57回日本癌治療学会学術集会，2019.10.24.
30) 高野利実：HER2陽性乳癌薬物療法の新展開 ﾒﾃﾞｨｶﾙｾﾐﾅｰ22．第29回日本医療薬学会年会，2019.11.3.
31) 近藤千紘、三浦裕司、尾崎由記範、増田淳、田辺裕子、野々垣清美、佐藤仁美、大関江理子、高野利実：がん薬物療法における味覚障害・栄養の実態調査．PS14-19第4回日本がんｻﾎﾟｰﾃｨﾌﾞｹｱ学会学術集会，青森，2019.9.7.
32) 味八木寿子、松本光史、二村学、鶴谷純司、井本滋、土井美帆子、徳永伸也、青儀健二郎、喜多川浩一、相良安昭、馬場基、永井成勲、高野利実：周術期乳癌に対するdose dense AC療法の嘔吐対策としてのﾃﾞｷｻﾒﾀｿﾞﾝの使用実態 -WJOG9016B試験- PS15-05．第4回日本がんｻﾎﾟｰﾃｨﾌﾞｹｱ学会学術集会，青森，2019.9.7.
33) Ozaki Y: HER2陰性転移性乳癌に対するﾆﾎﾞﾙﾏﾌﾞ+ﾍﾞﾊﾞｼｽﾞﾏﾌﾞ+ﾊﾟｸﾘﾀｷｾﾙ併用療法の第II相試験．日本乳癌学会・日本臨床腫瘍学会合同ｼﾝﾎﾟｼﾞｳﾑ1．日本乳癌学会，2019.
34) Ozaki Y: 骨転移・病的骨折に対する集学的・多職種ﾏﾈｰｼﾞﾒﾝﾄを考察する．ﾊﾟﾈﾙﾃﾞｨｽｶｯｼｮﾝ，日本乳癌学会2019.
35) 近藤千紘、山中太郎、三浦裕司、尾崎由記範、田辺裕子、矢野晶大、荻原喜一、小川貢平、永本将一、阪口和滋、浦上慎司、岡根谷利一、高野利実. 当院における進行腎がん透析症例の薬物療法. 第50回 腎癌研究会 P-18，2019.
2018年
2) Yoshiyuki Yamamoto, Wataru Okamoto, Akitaka Makiyama, Kohei Shitara, Tadamichi Denda, Takashi Ogura, Yasuyuki Nakano, Tomohiro Nishina, Masato Komoda, Hiroki Hara, Yukinori Ozaki, HIsato Kawakami, Narikazu Boku, Ichinosuke Hyodo, Kentaro Yamazaki, Shuichi Hironaka, Kazuko Sakai, Takeharu Yamanaka, Kei Muro, Kazuto Nishio. Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). ASCO-GI 2018. Abstract#202833
3) Wataru Okamoto, Akitaka Makiyama, Yoshiyuki Yamamoto, Kohei Shitara, Tadamichi Denda, Naoki Izawa, Yasuyuki Nakano, Tomohiro Nishina, Taito Esaki, Hiroki Hara, Yukinori Ozaki, Hiroyuki Okuda, Narikazu Boku, Ichinosuke Hyodo, Kentaro Yamazaki, Shuichi Hironaka, Kazuko Sakai, Takeharu Yamanaka, Kei Muro, Kazuto Nishio. Plasma VEGF-A (pVEGF-A) level in efficacy analysis of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV)(WJOG7612GTR). ASCO GI 2018. Abstract#202589.
4) 田村 宜子、栗川 美智子、田中 希世、小林 蓉子、小倉 拓也、門脇 正美、三浦 大周、中澤 英樹、佐藤 順一郎、木脇 圭一、藤井 丈士、増田 淳、尾崎 由記範、田辺 裕子、高野 利実、川端 英孝. ホルモン受容体陽性HER2受容体陰性乳癌の治療方針におけるOncotype®の意義-PSを用いたマッチコホート研究-.日本乳癌学会2018年.a91769.
5) 小林 蓉子、栗川 美智子、田中 希世、小倉 拓也、田村 宜子、門脇 正美、三浦 大周、中澤 英樹、佐藤 順一郎、木脇 圭一、藤井 丈士、増田 淳、尾崎 由記範、田辺 裕子、高野 利実、川端 英孝. dose- dense AC療法54例の薬物療法前後の病理学的変化と、造影MRI広がりパターンの検討. 日本乳癌学会2018年.
6) 栗川美智子、田村宜子、田中希世、小林蓉子、佐藤順一朗、尾崎由記範、木脇圭一、小倉拓也、近藤千紘、田辺裕子、門脇正美、三浦大周、中澤英樹、高野利実、藤井丈士、川端英孝. 転移性再発乳癌に対するエリブリン施行前後での新規遠隔転移出現の変化. 日本乳癌学会2018年.
7) Hiromichi Nakajima, Naoko Inoshita, Chihiro Kondoh, Yukinori Ozaki, Kenji Tomizawa, Yutaka Hanaoka, Shigeo Toda, Yuko Tanabe, Yuji Miura, Jin Moriyama, Shuichiro Matoba, Hiroya Kuroyanagi and Toshimi Takano. Combined analysis of tumor budding and tumor microenvironment in patients with stage III colorectal cancer. ASCO-GI 2018. Poster #652
8) Yukinori Ozaki, Koji Matsumoto, Masato Takahashi, Toru Mukohara, Manabu Futamura, Norikazu Masuda, Junji Tsurutani, Kenichi Yoshimura, Hironobu Minami, Toshimi Takano. Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial). J Clin Oncol 36, 2018 (suppl; abstr TPS1110). 2018 ASCO annual meeting.
9) Taito Esaki, Hiroshi Tsukuda, Nozomu Machida, Hiroyasu Ishida, Shigenori Kadowaki, Keiko Minashi, Shinya Tokunaga, Yukinori Ozaki, Chihiro Kondoh, Akitaka Makiyama, Yasutaka Sukawa, Takeharu Yamanaka, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro. A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT). JSMO 2018.
10) 増田淳, 尾崎由記範, 木澤莉香, 高橋萌々子, 大木遼介, 中島裕理, 栗川美智子, 小林蓉子, 近藤千紘, 小倉拓也, 田村宜子, 田辺裕子, 三浦裕司, 川端英孝, 高野利実, 乳癌周術期化学療法におけるdose-dense (dd) AC療法とFEC療法の安全性に関する後方視的研究. JSMO 2018.
11) 小塚 拓洋、尾崎 由記範 、中島 裕理、冨永 理人、宇木 章喜、井下 尚子、高野 利実. Combined radiotherapy and pembrolizumab for metastatic spinal cord compression from malignant melanoma: a case report. JSMO 2018. 50543.
12) 工藤千恵、河村 真美、荻原 大和、尾崎 由記範. Biological and immunological mechanisms underlying metastatic tumor burst. 日本癌学会学術集会 2018.9.27-29.
13) Miura Y. Immunotherapy for renal cell carcinoma: the differences from melanoma. SY7-1, JSMO, Kobe, Japan. 2018 Ann of Oncol 29 Suppl_7, 1 October 2018
14) Yukinori Ozaki, Shigehisa Kitano, Koji Matsumoto, Masato Takahashi, Toru Mukohara, Manabu Futamura, Norikazu Masuda, Junji Tsurutani, Kenichi Yoshimura, Hironobu Minami, Toshimi Takano. Biomarker study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917BTR). OT1-12-02. SABCS 2018.
15) C Kondoh. An overview of medical treatment in urothelial cancers. AntiCancer Treatment Japan 2018 Congress. S1-3.
16) C Kondoh. Case presentation -Muscle weakness-. Japanese Society of Renal Cancer 2018 Congress．
17) 近藤千紘, 松原雄. 症例から考えるOnco-Nephrology -実臨床における腎臓内科医とオンコロジストの協働-. 第3回 日本がんサポーティブケア学会
18) Miura Y.ADT and chemotherapy in oligometastatic prostate cancer. Multidisciplinary tumour board, November 2018 ESMO Asia, Singapore.
2017年
2) Y. Ozaki, M. Takahashi, H. Nakajima, R. Ohki, J. Masuda, C. Kondoh, Y. Miura, Y. Tanabe. T. Takano. Retrospective study of atypical femoral fracture in patients with malignant bone metastasis receiving denosumab therapy: case series. ESMO Asia 2017. Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676. Abstract 1171.
3) 栗川美智子、小倉拓也、田中希世、佐藤順一朗、尾崎由記範、木脇圭一、近藤千紘、田辺裕子、田村宜子、門脇正美、三浦大周、中澤英樹、高野利実、藤井丈士、川端英孝. 術前化学療法によるサブタイプ別の治療効果とその予後の検討. 日本乳癌学会2017.
4) 川端 英孝、栗川美智子、田中希世、小倉 拓也、田村 宜子、門脇 正美、三浦 大周、中澤 英樹、新井 正美、佐藤順一朗、木脇圭一、藤井丈士、尾崎 由記範、近藤千紘、田辺 裕子、高野 利実. BRCA1/2遺伝子の病的変異を背景とした乳癌症例の臨床病理学的特徴について. 日本乳癌学会2017.
5) Yukinori Ozaki, Momoko Takahashi, Hiromichi Nakajima, Ryosuke Ohki, Jun Masuda, Chihiro Kondoh, Yuji Miura, Yuko Tanabe, Toshimi Takano. Atypical femoral fracture in patients with malignant bone metastasis receiving denosumab therapy: retrospective study. 2017 Palliative and Supportive Care in Oncology Symposium. Abstract #197675.
6) Ryosuke Oki, Chihiro Kondoh, Yuji Miura, Yukinori Ozaki, Yuko Tanabe, Kazushige Sakaguchi, Kazuhiro Kurosawa, Shinji Urakami, Toshikazu Okaneya, Toshimi Takano. S-1 plus cisplatin combination therapy in patients with urachal carcinoma; a retrospective study. ESMO Asia 2017. Abstract 1302.
7) 近藤 千紘、 尾崎 由記範、田辺 裕子、三浦 裕司、白石 英馨、岸 晶子、林 伸和、高野 利実. 病勢進行後のニボルマブ治療の意義. 日本泌尿器腫瘍学会 2017.
8) Ryosuke Oki, Chihiro Kondoh, Yuji Miura, Yukinori Ozaki, Yuko Tanabe, Kazushige Sakaguchi, Kazuhiro Kurosawa, Shinji Urakami, Toshikazu Okaneya, Toshimi Takano. S-1 plus cisplatin combination therapy in patients with urachal carcinoma in Toranomon Hospital. 日本泌尿器腫瘍学会 2017.
2016年
2) Y. Sukawa, K. Nosho, Y. Miura, T. Takano, M. Ito, K. Yonesaka, M. Mori, S. Tokunaga, J. Kawada, H. Okuda, T. Sakamoto, Y. Hirashima, K. Uchino, Y. Miyata, K. Yoshimura, K. Yamazaki, S. Hironaka, N. Boku, I. Hyodo, K. Muro. Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab (Tmab) for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study. Abstract # 630, ESMO 2016 Congress, Copenhagen, Denmark. Annals of Oncology 27 (6), 2016.
3) Shigehiro Koganemaru, Naoko Inoshita, Yuji Miura, Yudai Fukui, Yukinori Ozaki, Kenji Tomizawa, Yutaka Hanaoka, Shigeo Toda, Koichi Suyama, Yuko Tanabe, Jin Moriyama, Takeshi Fujii, Shuichiro Matoba, Hiroya Kuroyanagi, Toshimi Takano. Prognostic significance of programmed death-ligand 1 (PD-L1) expression on tumor infiltrating immune cells (IC) in patients with Stage IIIb colorectal cancer. ASCO GI 2016. J Clin Oncol 34, 2016 (suppl 4S; abstr 611)
4) Miura Y, Inoshita N, Ozaki Y, Tanabe Y, Suyama K, Ikeda M, Okaneya T, Takano T. The loss if BAP1 protein expression in the first recurrence site of metastasis predicts poor prognosis. Abstr. # 599, 2016 ASCO-Genitourinary Cancers Symposium, San Francisco. J Clin Oncol 34, 2016 (suppl 2S; abstr 599)
5) 小倉拓也、川端英孝、田村宜子、門脇正美、三浦大周、中澤英樹、熊川孝三、新井正美、尾崎由記範、田辺裕子、高野利実：遺伝性乳癌卵巣癌症候群に対する当院の取り組みについて 2016年乳癌学会.
6) Yukinori Ozaki, Nobuko Tamura, Miyuki Utiyama, Jun Masuda, Shigehiro Koganemaru, Yuji Miura, Yuko Tanabe, Takuya Ogura, Masami Kadowaki, Daishu Miura, Hidetaka Kawabata, Toshimi Takano. Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: retrospective study. Cancer Res 2016;76(4 Suppl):Abstract nr P5-12-11.
7) 田村 宜子、小倉 拓也、三浦 大周、木脇 圭一、藤井 丈士、尾崎 由記範、田辺 裕子、高野 利実、中澤 英樹、門脇 正美、川端 英孝. ホルモン受容体陽性HER2 受容体陰性乳がんの臨床病理学的因子とオンコタイプDX、その予後. 乳癌学会2016. DP-1-13-5
8) 小倉 拓也、尾崎 由記範、木脇 圭一、田村 宜子、田辺 裕子、門脇 正美、三浦 大周、中澤 英樹、高野 利実、藤井 丈士、川端 英孝. 乳癌術前化学療法における治療効果とその予後の検討.乳癌学会2016. DP-2-68-3
9) 川端 英孝、小倉 拓也、田村 宜子、三浦 大周、門脇 正美、中澤 英樹、新井 正美、木脇 圭一、藤井 丈士、尾崎 由記範、田辺 裕子、高野 利実. BRCA 遺伝子変異陽性及び陰性乳癌の臨床・病理学的特徴について. 乳癌学会 2016. DP-1-17-2.
10) Toshimi Takano,Ayako Matsuda, Noriko Ishizuka, Yukinori Ozaki, Koichi Suyama, Yuko Tanabe, Yuji Miura, Eisuke Matsushima. Effectiveness of self-help workbook intervention on quality of life in cancer patients receiving chemotherapy: Results of a randomized controlled trial. ASCO 2016. 10070.
11) Shigehiro Koganemaru, Naoko Inoshita, Yuji Miura, Yudai Fukui, Yukinori Ozaki, Kenji Tomizawa, Yutaka Hanaoka, Shigeo Toda, Koichi Suyama, Yuko Tanabe, Jin Moriyama, Takeshi Fujii, Shuichiro Matoba, Hiroya Kuroyanagi, Toshimi Takano. Prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with stage III colorectal cancer. JCO Vol 34, No 15_suppl (May 20 Supplement), 2016: 3568
12) 高野利実、松田彩子、石塚典子、尾崎由記範、陶山浩一、田辺裕子、三浦裕司、松島英介. 外来化学療法中のがん患者に対するワークブック介入効果を評価するランダム化比較試験：QOL改善効果の報告. JPOS2016.
13) 増田 淳、尾崎 由記範、近藤 千紘、小倉 拓也、田村 宣子、三浦 裕司、田辺 裕子、三浦 大周、川端 英孝、高野 利実. 乳癌の周術期化学療法におけるdose-dense AC療法のfeasibilityに関する後方視的研究. 乳癌学会2016.
14) Yukinori Ozaki, Nobuko Tamura, Oki Ryosuke, Hiromichi Nakajima, Miyuki Uchiyama, Jun Masuda, Chihiro Kondoh, Yuji Miura, Yuko Tanabe, Takuya Ogura, Masami Kadowaki, Daishu Miura, Hidetaka Kawabata, Toshimi Takano. Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer. JSMO2016. P2-017.
15) Taro Funakoshi , Takahiro Horimatsu, Michio Nakamura, Koichi Suyama, Takurou Mizukami, Shuji Arita, Yukinori Ozaki , Hisateru Yasui , Hironaga Satake , Masanori Toyoda , Shujiro Yazumi, Toshihiko Kirishima , Akira Nozaki , Akira Yoshioka, Takeshi Matsubara, Motoko Yanagita , Shunichi Fukuhara, Manabu Muto , J-CANDY Group. Management of chemotherapy in cancer patients undergoing hemodialysis： Results of a multicenter study. ESMO2016.
16) Yuko Tanabe, Seiji Shiraishi, Daisuke Nishizawa, Akinobu Hamada, Junko Hasegawa, Yukinori Ozaki, Nobuko Tamura, Akihiko Shimomura, Mayu Yunomawa, Kan Yonemori, Toshimi Takano, Hidetaka Kawabata, Kazutaka Ikeda, Kenji Tamura, Yasuhiro Fujiwara, Chikako Shimizu. Paclitaxel-induced sensory peripheral neuropathy is associated with the SCN9A genetic variant. European Society for Medical Oncology 2016 Congress, 7-11, October 2016. Ann Oncol (2016) 27 (suppl_6): 137P.
17) Matsumoto K*, Takahashi M, Sato K, Takano T, Ryushima Y, Doi M, Aogi K, Fujiwara K, Tamura K, Hosoda M, Tokunaga S, Makiyama A, Miyamoto K, Hozumi Y, Yanagihara K, Imamura C, Chiba Y, Nakamura S, Saeki T. Palonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide (AC) regimen, 2015 ASCO Annual Meeting Abstr 9598, June 2016
*Hyogo Cancer Center, Hyogo, Japan
2015年
*Teikyo University, Tokyo, Japan
2) Miura Y, Takano T, Sukawa Y, et al. A phase II trial of 5-weekly S-1 plus cisplatin (CDDP) combination with trastuzumab (Tmab) for HER2-positive advanced gastric or esophagogastric junction (EGJ) cancer: WJOG7212G (T-SPACE) study, 2015 Gastrointestinal Cancers Symposium. abstr126, January 15-17, 2015
3) Shimizu C*, Tanabe Y, Hamada A, Yunokawa M, Takano T, Koganemaru S, Ozaki Y, Tamura N, Fujiwara Y, Tamura K. Association of paclitaxel-induced sensory peripheral neuropathy with the ABCB1 genetic variant and age, 2015 ASCO Annual Meeting abstr 11100, June 2016
*National Cancer Center Hospital, Tokyo, Japan
4) 高野利実. 乳がん治療の最前線, 第19回日本緩和医療学会教育セミナー, 2015年6月18日
5) 高野利実. 腫瘍内科医として進行癌患者を支えるということ, 第20回日本緩和医療学会学術大会 シンポジウム20「終末期におけるたった一度の意思決定を支える」, 2015年6月20日
6) 高野利実. ホルモン受容体陽性転移・再発乳がんに対するタモキシフェンのCYP2D6遺伝子型に基づく個別化投薬と固定用量の比較研究 TARGET (Tamoxifen Response by CYP2D6 Genotype-based Treatment)-1 Study (OS-1-01-05) 第23回 日本乳癌学会学術総会 厳選口演 2015年7月2日
7) 高野利実. 発熱性好中球減少症の予防とG-CSFの適正使用(SY-2-14-04), 第23回 日本乳癌学会学術総会 日本乳癌学会/日本臨床腫瘍学会 合同シンポジウム「乳癌薬物療法の有害事象の克服を目指して」, 2015年7月3日
8) Tanabe Y, Shimizu C, Hashimoto J, Kodaira M, Yamamoto H, Yunomawa M, Yonemori K, Takano T, Fujiwara Y, Tamura K. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?, 第13回日本臨床腫瘍学会学術集会, 2015年7月17日
9) 高野利実. 日本の現状と展望, 第13回日本臨床腫瘍学会学術集会 会長シンポジウム「がん薬物療法専門医1000人到達記念企画② がん薬物療法専門医のキャリア形成（米国に学ぶ）」, 2015年7月18日
10) 高野利実. 乳がん薬物療法の止め時と患者サポート, 第13回日本臨床腫瘍学会学術集会 シンポジウム (SY14)「医師が考える『抗がん薬』の止め時と患者サポート」, 2015年7月18日
11) 高野利実. 乳癌,第26回日本臨床腫瘍学会教育セミナー, 2015年8月1日
12) 高野利実、松田彩子、石塚典子、尾崎由記範、陶山浩一、三浦裕司、松島英介. 外来化学療法中の乳癌患者へのワークブック介入によるQOL改善効果～ランダム化比較試験初回解析結果報告～, 第28回日本サイコオンコロジー学会総会 一般口演 O4-5, 2015年9月18日
13) Kuwayama T*, Yamauchi H, Takano T, et al. Primary analysis of a randomized phase II, multicenter trial: Neoadjuvant weekly Nab-paclitaxel 100mg/m2 followed by FE100C compared with Docetaxel 75mg/m2 followed by FE100C for early breast cancer in Japan, 2015 Breast Cancer Symposium, September 25-27, 2015 Abstr 136
*Showa University, Tokyo, Japan
14) Fujita Y*, Yamazaki K, Oba MS, Muro K, Negoro Y, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Seki N, Sato M, Ebi M, Tamagawa H, Ueda S, Tamura T, Boku N, Hyodo I, Yamanaka T, Tsurutani J, and Nishio K. Exploratory analysis of predictive biomarkers of oxaliplatin versus irinotecan in combination with bevacizumab for patients with metastatic colorectal cancer in WJOG4407G study, European Cancer Congress 2015, September 27 2015
*West Japan Oncology Group, Osaka, Japan
15) 高野利実. ペグフィルグラスチムに関する改訂のポイントと乳癌診療における意義, 第53回日本癌治療学会学術集会 G‑CSF適正使用ガイドライン一部改訂にかかるコンセンサスミーティング, 2015年10月30日
16) 高野利実. HER2陽性転移性乳癌の薬物療法の考え方, 第5回 乳がん分子標的治療研究会, 2015年11月7日
17) Nakajima H, Koganemaru S, Miura Y, Ozaki Y, Tanabe Y, Inoshita N, Fujii T, Tanabe H, Takano T. The role of chemotherapy for locally advanced primary cardiac angiosarcoma. ESMO Asia 2015. Singapore, 18-21 December, 2015 YO43
18) Masuda J, Ozaki Y, Koganemaru S, Miura Y, Tanabe Y, Ogura T, Tamura N, Miura D, Kawabata H, Takano T. Feasibility of dose-dense doxorubicin and cyclophosphamide (AC) followed by taxane (T) in Japanese women with early breast cancer: A retrospective study, ESMO Asia 2015, 18-21 December, 2015 104P
19) 尾崎由記範、三浦裕司、高野利実. Regorafenib for patients with metastatic colorectal cancer and GIST; retrospective case series and our approach to manage toxicities, 日本肉腫学会記念シンポジウム, 2015年12月3日
20) Ozaki Y, Tamura N, Utiyama M, Masuda J, Koganemaru S, Miura Y, Tanabe Y, Ogura T, Kadowaki M, Miura D, Kawabata H, Takano T. Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: retrospective study. 2015 San Antonio Breast Cancer Symposium, December 8-12, 2015 P5-12-11
21) Miura Y, Takano T, Sukawa Y, Nosho K, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Tsuda M, Taku K, Nishikawa K, Moriwaki T, Yoshimura K, Boku N, Hyodo I. A phase II trial of 5-weekly S-1 plus cisplatin (CDDP) combined with trastuzumab (Tmab) for HER2-positive advanced gastric or esophagogastric junction (EGJ) cancer: WJOG7212G (T-SPACE) study. J Clin Oncol 33, 2015 (suppl 3; abstr126)
22) H. Nakajima, S. Koganemaru, Y. Miura, Y. Ozaki, Y. Tanabe, N. Inoshita, T. Fujii, H. Tanabe, T. Takano. The Role of Chemotherapy for Locally Advanced Primary Cardiac Angiosarcoma. ESMO Asia 2015.
23) Jun Masuda, Yukinori Ozaki, Shigehiro Koganemaru, Yuji Miura, Yuko Tanabe, Takuya Ogura, Nobuko Tamura, Daishu Miura, Hidetaka Kawabata, Toshimi Takano. Feasibility of dose-dense doxorubicin and cyclophosphamide (AC) followed by taxane (T) in Japanese women with early breast cancer: A retrospective study. Annals of Oncology 26(suppl 9):30-30 · December 2015.
24) Chikako Shimizu, Yuko Tanabe, Akinobu Hamada, Mayu Yunokawa, Toshimi Takano, Shigehiro Koganemaru, Ozaki Yukinori, Nobuko Tamura, Yasuhiro Fujiwara, Kenji Tamura. Association of paclitaxel-induced sensory peripheral neuropathy with the ABCB1 genetic variant and age. J Clin Oncol 33, 2015 (suppl; abstr 11100). ASCO 2015 poster 11100.
25) Yukinori Ozaki. Regorafenib for patients with metastatic colorectal cancer and GIST; retrospective case series and our approach to manage toxicities. 肉腫学会2015.
2014年
2) Hara F*, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Takashima T, Watanabe T, Sagara Y, Nishimura R, and Ohashi Y. Randomized phase III study of taxane versus TS-1 as first-line treatment for metastatic breast cancer (SELECT BC), 2014 ASCO Annual Meeting Abstr 1012, June 2014
*Shikoku Cancer Center
3) Miura Y, Imamura CK, Uchino K, Kishida T, Matsubara N, Shinojima T, Oya M, Nakaigawa N, Yoshimura K, Takano T, Tanigawara Y. Dose adjustment of axitinib based on AUC monitoring in sunitinib-refractory advanced renal cell carcinoma, 2014 ASCO Annual Meeting TPS4598, June 2014
4) Miura Y, Fujii Y, Shimomura A, Sudo N, Ikeda M, Suyama K, Abe M, Kameyama S, Okaneya T, and Takano T. Temporal cessation of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective study, 2014 ASCO Annual Meeting e15552, June 2014
5) 高野利実. 腫瘍内科医と緩和ケア医の連携, 第19回日本緩和医療学会学術大会 シンポジウム9「医師―医師間のコミュニケーションを振り返る」, 2014年6月20日
6) Tamagawa H*, Yamazaki K, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Takahashi Y, Hirashima T, Ebi M, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Yamaguchi K, Ando M, Morita S, Boku N, and Hyodo I. Prespecified subgroup analyses in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus Bevacizumab as first-line treatment for metastatic colorectal cancer (P-0211), ESMO 16th World Congress on Gastrointestinal Cancer, June 25-28, 2014, Barcelona, Spain
*Osaka General Medical Center
7) 高野利実. 術前抗HER2療法の最新知見, 第22回日本乳癌学会学術総会 シンポジウム1「術前薬物療法」, 2014年7月10日
8) 高野利実. 抗HER2療法のバイオマーカー, 第22回日本乳癌学会学術総会 シンポジウム8「抗HER2療法（進行再発乳癌）」, 2014年7月11日
9) 高野利実、蔵並勝、雷哲明、増田慎三、佐伯俊昭、中村清吾、伊藤良則、徳田裕、田村和夫. 乳癌術前/術後TC療法実施時の発熱性好中球減少症に対するKRN125(Pegfilgrastim)の第III相試験:全期間の報告, 第22回日本乳癌学会学術総会, 2014年7月12日
10) 下村昭彦、三浦裕司、福司佳穂里、伊藤忠明、陶山浩一、三浦大周、川端英孝、林昌洋、高野利実. Child-Pugh分類Aの肝障害を有する乳癌患者に対するEribulinの安全性に関する単施設後方視的研究, 第12回日本臨床腫瘍学会学術集会, 2014年7月17日
11) Miura Y, Shimomura A, Sudo N, Ikeda K, Suyama K, Abe M, Kameyama S, Okaneya T, Takano T. Temporal Cessation of Sunitinib Treatment in Patients with Metastatic Renal Cell Carcinoma: a retrospective study, 第12回日本臨床腫瘍学会学術集会, 2014年7月17日
12) 高野利実. HER2陽性乳癌における個別化治療, 第12回日本臨床腫瘍学会学術集会 JSMO/JBCS ジョイントシンポジウム, 2014年7月19日
13) 陶山浩一、小金丸茂博、尾崎由記範、三浦裕司、高野利実. 腹部症状を伴うFN症例に注意, 第12回日本臨床腫瘍学会学術集会 専門医ケースカンファレンス, 2014年7月19日
14) 高野利実. 一次予防的投与, 第52回日本癌治療学会学術集会 G‑CSF適正使用ガイドライン一部改訂のためのコンセンサスミーティング, 2014年8月29日
15) 高野利実. ペグフィルグラスチム, 第52回日本癌治療学会学術集会 G‑CSF適正使用ガイドライン一部改訂のためのコンセンサスミーティング, 2014年8月29日
16) 高野利実. 診断時からの緩和ケアをどう提供するか ～緩和ケアって特別なもの？～, 第52回日本癌治療学会学術集会 臓器別シンポジウム09「がん緩和治療戦略のUp to Date」, 2014年8月29日
17) 高野利実. 支持療法, 第52回日本癌治療学会学術集会 教育セッション, 2014年8月30日
18) Body JJ*, Bone HG, Van Poznak C, de Boer R, Stopeck A, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Wang H, Bracco OL, Balakumaran A, and Kostenuik PJ. Risk Factors for Hypocalcemia in Patients with Cancer Receiving Denosumab, European Society for Medical Oncology (ESMO) 2014 Congress 1513P 28 September, 2014
*CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
19) 高野利実. 腫瘍内科の診察室でがん患者と向き合って, 第27回日本サイコオンコロジー学会 日本臨床腫瘍学会合同シンポジウム「がん患者指導管理の充実と精神腫瘍学的サポート」, 2014年10月4日
20) Body JJ*, Bone HG, Van Poznak C, de Boer R, Stopeck A, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Wang H, Bracco OL, Balakumaran A, and Kostenuik PJ. Risk Factors for Hypocalcemia in Patients with Cancer Receiving Denosumab, The 41st Annual Scientific Meeting of the Clinical Oncological Society of Australia, 2014
*CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
21) de Boer RH*, Body JJ, Bone HG, Van Poznak C, Stopeck A, Damião R, Fizazi K, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Wang H, Bracco OL, Balakumaran A, and Kostenuik PJ. Risk Factors for Hypocalcaemia in Patients with Cancer Receiving Denosumab, the Clinical Oncology Society of Australia (COSA) annual scientific meeting, December 2, 2014
*Royal Melbourne Hospital, Melbourne, Victoria, Australia
22) Tomizawa K, Suyama K, Miura Y, Shimomura A, Hanaoka Y, Toda S, Moriyama J, Matoba S, Kumada H, Takano T, Kuroyanagi H. The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection. J Clin Oncol 32, 2014 (suppl 3; abstr 629)
23) Miura Y, Imamura CK, Uchino K, Kishida T, Matsubara N, Shinojima T, Oya M, Nakaigawa N, Yoshimura K, Takano T, Tanigawara Y. Dose adjustment of axitinib based on AUC monitoring in sunitinib-refractory advanced renal cell carcinoma. J Clin Oncol 32:5s, 2014 (suppl; abstr. TPS4598)
24) Miura Y, Fujii Y, Shimomura A, Sudo N, Ikeda M, Suyama K, Abe M, Kameyama S, Okaneya T, Takano T. Temporal cessation of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective study. J Clin Oncol 32, 2014 (suppl; abstr e15552)
2013年
*CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
2) Higaki K*, Masuda N, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M. Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study), 2013 ASCO Annual Meeting J Clin Oncol 31, 2013 (suppl; abstr 1048)
*Hiroshima City Hospital
3) Ryu MH*, Baba E, Lee KH, Boku N, Park YI, Hyodo I, Nam BH, Esaki T, Ryoo BY, Song EK, Cho S, Lee SS, Kang WK, Yang SH, Zang DY, Shin DB, Park SR, Shinozaki K, Takano T, Kang YK. on behalf of SOS Investigators: Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study, 2013 ASCO Annual Meeting J Clin Oncol 31, 2013 (suppl; abstr LBA4024)
*Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
4) Yamamoto N, Yamashiro H, Iwata H, Masuda N, Ohtani S, Takahashi M, Yamazaki K, Kato M, Ohno S, Kuroi K, Yamagami K, Morimoto T, Hasegawa Y, Takano T, Kadoya T, Hosoda M, Abe H, Morita S, Yasuno S, Toi M. Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01), 2013 ASCO Annual Meeting J Clin Oncol 31, 2013 (suppl; abstr 613)
*Department of Breast and Endocrine, Surgery, Graduate School of Medical, Sciences, Kumamoto University
5) 高野利実. 再発部位別治療選択, 第21回日本乳癌学会学術総会治療プレナリーセッション2 転移乳癌治療 ～サブタイプを考慮した再発後の治療戦略～, 2013年6月28日
6) 高野利実. 転移性乳癌の薬物療法, 第21回日本乳癌学会学術総会教育セミナー, 2013年6月28日
7) 高野利実. 術前・術後TC療法の位置づけ ～「より多く、より強く」から「必要な治療を、適切に」の時代へ～, 第21回日本乳癌学会学術総会 ランチョンセミナー22, 2013年6月29日
8) Takano T. Patient and Survivor Care, Best of ASCO 2013 in Japan, July 6, 2013
9) 三浦裕司. Personalized therapy with molecular targeted agents for renal cell carcinoma, using pharmacokinetic, pharmacodynamics and pharmacogenetics analyses(WS3-2), 第11回日本臨床腫瘍学会学術集会, 2013年8月29日
10) 福井雄大、下村昭彦、小金丸茂博、陶山浩一、三浦裕司、新藤昇、高野利実. 当院における皮下埋め込み型中心静脈ポート感染におけるリスク因子の検討, 第51回日本癌治療学会学術集会, 2013年10月
11) Martín M*, Stopeck AT, Lipton A, Body JJ, Paterson A, Steger GG, Tonkin K, de Boer RH, Fujiwara Y, Yardley D, Jassem J, Takano T, Solal-Celigny P, Fan M, Chung K, Braun A. Denosumab en pacientes con cáncer de mama y metástasis óseas tratados previamente con Ácido Zoledrónico (AZ) o Denosumab: resultados de la fase abierta de extensión de 2 años de un ensayo pivotal de fase 3, Congreso Nacional de Oncologia Media, Salamanca, October 23-25, 2013
*Hospital General Universitario Gregorio Marañón, Madrid, Spain
12) 高野利実. 化学療法に伴う悪心嘔吐, 第51回日本癌治療学会学術集会 プレナリーセッションレビュー, 2013年10月26日
13) 高野利実. 発熱性好中球減少症の予防 ～G-CSFの役割を中心に～, 第51回日本癌治療学会学術集会 学術セミナー36, 2013年10月26日
14) de Boer RH*, Body JJ, Lipton A, Stopeck A, Fizazi K, Bone HG, Saad F, Van Poznak C, Shore N, Ibrahim T, Takano T, Damiao R, Wang H, Kostenuik PJ, Shaywitz A, Bracco O, Braun A. Hypocalcaemia in patients with metastatic bone disease receiving denosumab, The 40th Annual Scientific Meeting of the Clinical Oncological Society of Australia November 12-14, 2013
*Royal Melbourne Hospital, Melbourne, Victoria, Australia
15) Sato N*, Masuda N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka S, Toi M. A randomized study of docetaxel + cyclophosphamide (TC), 5-fluorouracil + epirubicin + cyclophosphamide (FEC)-TC, and TC-FEC as preoperative chemotherapy for hormone receptor-positive and HER2-negative primary breast cancer: Japan Breast Cancer Research Group (JBCRG) – 09 San Antonio Breast Cancer Symposium P3-14-05, December 12, 2013
* Niigata Cancer Center Hospital
16) Miura Y, Naito Y, Shimomura A, Iwatani T, Miura D, Kawabata H, Takano T. The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. Eur J Cancer 47:suppl 1, S240 (abstr. #3059)
17) Miura Y. Personalized therapy with molecular targeted agents for renal cell carcinoma, using pharmacokinetic, pharmacodynamics and pharmacogenetics analyses. (Workshop 3: Cooperation of medical oncologist and urologist in molecular target therapy of renal cancer, WS3-2) Japanese Society of Medical Oncology 11th, 2013
2012年
2) Stopeck AT, Lipton A, Martín M, Body J-J, Paterson A, Steger GG, Tonkin K, de Boer RH, Fujiwara Y, Yardley D, Jassem J, Takano T, Solal-Celigny P, Fan M, and Braun A. Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab, 4th Asian Oncology Summit, SingaporeApril 13-15, 2012
3) Takano T, Kimura H, Nishio K, et al. WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes, American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL2012年6月
4) Masuda N, Sato N, Higaki K, Kashiwaba M, Matsunami N, Takano T, Yamamura J, Kaneko K, Takahashi M, Ohno S, Fujisawa T, Tsuyuki S, Miyoshi Y, Ohtani S, Yamamoto Y, Bando H, Onoda T, Kawabata H, Morita S, Ueno T, Toi M. A prospective multicenter randomized phase II neo-adjuvant study of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) followed by docetaxel, cyclophosphamide and trastuzumab (TCH) versus TCH followed by FEC versus TCH alone, in patients (pts) with operable HER2 positive breast cancer: JBCRG-10 study (UMIN000002365), San Antonio Breast Cancer Symposium, December 4-8, 2012
5) 高野利実. 日本臨床腫瘍学会がん薬物療法専門医と乳腺専門医（パネルディスカッション2）, 第20回日本乳癌学会学術総会, 2012年6月28日
6) 高野利実. 臨床試験の結果を吟味する－このデータはどう読むべきか－（CSPOR-BCサテライトシンポジウム）, 第20回日本乳癌学会学術総会, 2012年6月29日
7) 高野利実. 骨転移に対する治療（シンポジウム14「効果的薬物療法を目指した支持療法」）, 第10回日本臨床腫瘍学会学術集会, 2012年7月26日
8) 高野利実、田原総一朗、中川和彦ほか. がん患者の必要としているがん医療 ―地域でがん患者を支えるためには―, 第10回日本臨床腫瘍学会学術集会 公開シンポジウム, 2013年7月26日
9) 高野利実. 乳癌の術後薬物療法 「N+には化学療法が必須」（専門医会ケースカンファレンス）, 第10回日本臨床腫瘍学会学術集会, 2012年7月27日
10) 三浦裕司. 原発不明がん（専門医会ケースカンファレンス）, 第10回日本臨床腫瘍学会学術集会, 2012年7月27日
11) 高野利実. ASCO 2012 エーザイ Eribulin Round Table Discussion 2012, 年6月3日
12) 高野利実. 乳癌, 第19回日本臨床腫瘍学会教育セミナー, 2012年3月4日
13) TakanoT. The Rationale of ELTOP Study (WJOG6110B), WJOG 4th International Symposium, 2012年4月6日
14) Takano . Patient and Survivor Care, Best of ASCO 2012 in Japan, 2012年7月8日
15) 高野利実. 新しい骨転移治療（学術セミナー1）, 第50回日本癌治療学会学術集会, 2012年10月25日
16) 高野利実. 乳癌骨転移治療の新たな展開（スポンサードミニシンポジウム）, 第10回日本乳癌学会近畿地方会, 2012年11月24日
17) 高野利実. SABCS 2011報告, 第1回 東京乳癌 Wednesday Conference, 2012年1月18日
18) Suyama K, Miura Y, Okita R, Hasegawa R, Motoshima T, Kurosawa K, Okaneya T, Takano T, et al. Analysis of iron homeostasis in using everolimus for renal cell carcinoma. (abstr. #O-15) Japanese Society of Renal Cancer 43th, 2012
19) 小山隆文、尾崎由記範、大山優. Pneumocystis jirovecii pneumonia(PJP)in non-HIV infected patients with solid tumor. 第10回日本臨床腫瘍学会学術集会 2012年7月25日
20) 小山隆文、尾崎由記範、大山優. Pneumocystis jirovecii pneumonia in non-HIV infected patients with solid tumors. 第50回日本癌治療学会学術集会 2012年10月25日
21) 尾崎由記範、大山優. 進行平滑筋肉腫に対する定速静注GemcitabineおよびDocetaxel併用療法の安全性と有効性. 第50回日本癌治療学会学術集会 2012年10月25日
22) 中村能章、尾崎由記範、大山優. 心機能低下症例に対する化学療法の安全性、及び標準治療を可能にする背景因子についての解析. 第10回日本臨床腫瘍学会学術集会 2012年7月25日
23) 中村能章、尾崎由記範、大山優. 心機能低下症例に対する化学療法の解析. 第50回日本癌治療学会学術集会 2012年10月25日
2011年
2) Toshimi Takano. Anti-EGFR therapy: overview, Ann Oncol 22 (Suppl 9):ix26, 2011
3) Koichi Suyama, Takayuki Yoshino, Hideaki Bando, et al. Difference in overall survival in colorectal cancer patients with the KRAS p.G13D and other KRAS mutations after the failure of 5-fluorouracil, oxaliplatin, and irinotecan, 第9回日本臨床腫瘍学会学術集会, 2011年7月1日
4) Koichi Suyama, Takayuki Yoshino, Hideaki Bando, et al."Difference in overall survival in colorectal cancer patients with the KRAS p.G13D and other KRAS mutations after the failure of 5-fluorouracil, oxaliplatin, and irinotecan, The European Multidisciplinary Cancer Congress, Stockholm, 23 – 27 September 2011
5) 三浦裕司. 進行腎細胞癌の治療戦略, 第9回日本臨床腫瘍学会学術集会, 2011年7月22日
6) Yuji Miura, Yoichi Naito, Akihiko Shimomura, Tsuguo Iwatani, Daishu Miura, Hidetaka Kawabata, Toshimi Takano. The safety of chemotherapy for breast cancer patients with hepatitis C virus infection, The European Multidisciplinary Cancer Congress, ecco 16/ESMO 36, 2011年9月23-27日
7) 高野利実、藤原康弘、岩田広治、増田慎三. 骨転移を有する乳癌患者におけるデノスマブとゾレドロン酸の比較：データカットオフ後データを含む解析結果, 第19回日本乳癌学会学術総会, 2011年9月3日
8) Toshimi Takano. Investigator-driven clinical trials including translational research in Japan: West Japan Oncology Group (WJOG) (International session 10), Japanese Society of Medical Oncology 2012 Annual Meeting, 2012年7月23日
9) 高野利実. Anti-HER2 therapy and biomarkers（シンポジウム1 分子標的治療薬とバイオマーカー）, 第9回日本臨床腫瘍学会学術集会, 2011年7月21日
10) 高野利実. Overview （シンポジウム2 抗EGFR療法の新しい展開）, 第9回日本臨床腫瘍学会学術集会, 2011年7月21日
11) Stopeck A, Lipton A, Martín M, et al. Denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2-year open-label extension treatment phase of a pivotal phase 3 study, San Antonio Breast Cancer Symposium 2011(P6‐15‐11), December, 2011
12) Yamazaki K, Naito Y, Yuki S, et al. Validation study of a prognostic classification system in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy, J Clin Oncol 30, 2012 (suppl 4; abstr 624)
13) Shimomura A, Naito Y, Miura Y, et al. Interstitial lung disease associated with docetaxel in Japanese breast cancer patients – a retrospective analysis at a single institution, The 1st International Consensus Conference for Advanced Breast Cancer (ABC1), 2011年11月1日
14) Ishibashi M, Naito Y, Miura Y, et al. Paclitaxel-related interstitial lung disease: implication of mediastinal lymphadenopathy, The European Multidisciplinary Cancer Congress, Stockholm, 2011年9月26日
15) 内藤陽一. HER2陽性胃がん 手術不能例に対するハーセプチンの適応、使用方法（専門医会ケースカンファレンス）, 第9回日本臨床腫瘍学会学術集会, 2011年7月22日
16) Toshimi Takan.: Patient and Survivor Care, Best of ASCO 2011 in Japan, 2011年7月9日
2010年
2) Takano T. Patient and Survivor Care, Best of ASCO 2010 in Japan, 2010年7月
3) Takano T. EGFR mutations and survival benefit from EGFR-TKIs in lung cancer, The 3rd World Cancer Congress, Singapore, 2010年6月
4) Stopeck A, Martin M, Ritchie D, Body JJ, Paterson A, Viniegra M, Jassem J, Takano T, Van Poznak C, Bourgeois H, Fan M, Dansey R, Braun. A Effect of Denosumab Versus Zoledronic Acid Treatment in Patients With Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase, San Antonio Breast Cancer Symposium 2010, 2010年12月
5) K Yoh, K Kubota, H Ohmatsu, et al. A phase II trial of zoledronic acid in combination with cisplatin and docetaxel in non-small cell lung cancer patients with bone metastases, 2010 ASCO Annual Meeting J Clin Oncol 28, 2010 (suppl; abstr e18104)
6) H. Kenmotsu, K. Goto, Y. Ohe, et al. Analysis of disease recurrence in the central nervous system (CNS) in patients with non-small cell lung cancer (NSCLC) after responded to gefitinib, 2010 ASCO Annual Meeting J Clin Oncol 28, 2010 (suppl; abstr e18032)
7) Y Naito, K Kubota, Y Ohe, et al. Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell lung cancer, 2010 ASCO Annual Meeting J Clin Oncol 28, 2010 (suppl; abstr e18014)
8) Y Naito, K Kubota, Y Ohe, et al. LUNG CANCER IN NEVER-SMOKERS, The 35th ESMO Congress Annals of Oncology 21, 2010 (Supplement 8;abstr 378P)
9) Rugo H, Mukai H, Takano T, and Matsumoto .: State-of-the-Art Breast Cancer Treatments Roundtable Discussion with Dr. Hope Rugo, 2010年6月
10) 高野利実. ASCO 2010 Topics Part 2, BMKK Lunch Seminar in Chicago, 2010年6月
11) 高野利実. 転移性乳癌の薬物療法, Clinical Breast Cancer Conference, 2010年10月
2009年
2) Miura Y, et al. Safety and effectiveness of rehabilitation for elderly patients with hematological malignancies who received intensive chemotherapies. (abstr. #4014) Joint ECCO 15-34th ESMO Multidisciplinary Congress, BERLIN, 20-24 SEPTEMBER, 2009